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INTRODUCTION 
In 1987, we started octreotide receptor scintigraphy in humans. After a few years 
of using the radioiodinated [Tyrs]-octreotide,' we switched to [lllIn-DTPA-~-Phe*]- 
octreotide, which has many advantages over the radioiodinated Pa- 
tients with various forms of cancer, both classically known as neuroendocrine and 
nonendocrine, have been inve~tigated.~ 
The application of these new peptide-receptor agents in scintigraphy, and of 
many others that will become available in the near future, such as substance P and 
bombesin or their derivatives, might evoke a combination of optimism and pessi- 
mism. After all, the presence of receptors determines the possibility of detecting the 
abnormality or tumor by peptide receptor scintigraphy (PRS). Thus, the classical 
concept of false positives and false negatives really is not applicable to visualization 
by means of PRS.' This technique primarily allows an interpretation with regard to 
receptor presence and not to anatomical abnormalities, as is the case with CT, 
ultrasound, and MRI. Only at a second stage, after showing the localization of an 
abnormal density of receptors, one might conclude the presence of an anatomical 
abnormality expressing the peptide receptors, for example, a primary pancreatic islet 
cell tumor expressing somatostatin receptors. However, when PRS does not demon- 
strate (a) lesion(s), suggesting that a tumor or (several of the) metastases do not 
express (anymore) a certain peptide receptor, this also might be of paramount 
importance with regard to therapeutic advice to the patient. Dedifferentiation of a 
tumor is accompanied by loss of a given peptide receptor, and this information 
influences the oncologist's therapeutic decisions. An example is the choice between 
the use of somatostatin analogues or cytostatic drugs in patients with neuroendocrine 
tumors that are well differentiated or have become anaplastic, respectively.6*' With 
future (radio)therapy using (radio)labeled peptide(-derivatives), the presence (in the 
individual patient!) of several undifferentiated metastases, that do not bind a given 
(radio)ligand as opposed to the well-differentiated metastases, necessitates (an) 
'Address for correspondence: E. P. Krenning, M.D., Department of Nuclear Medicine, 
University Hospital Rotterdam, Dr Molewaterplein 40,3015 GD Rotterdam, the Netherlands. 
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additional application(s) of a (radio)ligand with appropriate binding characteristics 
for the undifferentiated tumors, possibly by injection of a "cocktail" of (radiolabeled) 
ligands. Thus, mapping of the presence (including the localization of the tumors and 
of the distribution) of peptide receptors on all metastases in the individual patient by 
PRS may become an attractive, noninvasive, harmless, easy-to-perform tool for an 
individual therapeutic approach of the cancer patient. 
In this report, we present a patient with an inoperable, metastasized glucagonoma 
in whom peptide receptor radiotherapy (PRRT) with Auger and conversion electrons 
emitting [lllIn-DTPA-~-Phel]-octreotide affects the growth of the tumor and the 
circulating glucagon levels. Because of their more appropriate physical character- 
istics, future nuclear radiotherapy is directed to the use of a- or p-particles emitting 
radionuclide-labeled peptides. 
SELECTION OF RADIONUCLIDE FOR RADIOTHERAPY 
WITH THE RADIOLABELED SOMATOSTATIN ANALOGUE 
PDTPA-D-P~~']-OCTREOTIDE 
For radiotherapeutic applications, several radionuclides have been proposed and 
investigated to be coupled to [DTPA-~-Phel]-octreotide. Radiolabeled [DTPA-D- 
Phell-octreotide has an appropriate distribution profile in humans for this purpose. 
At the moment, theoretically suitable P-emitting radionuclides are not available in 
pure form or show a dissociation from the chelated peptide in serum. Therefore, we 
decided to investigate the antiproliferative effect of the Auger and conversion elec- 
trons of ['ILIn- DTPA-~-Phel]-octreotide. FIGURE 1 and TABLES 1 and 2 illustrate the 
origin and the main physical characteristics of these electrons, respectively. 
MATERIAL AND METHODS 
[DTPA-o-Phe1]-octreotide and II1InCl, (370 MBq/mL in HCL, pH = 1.5-1.9) 
were obtained from Mallinckrodt Medical BV (Petten, the Netherlands). [DTPA- 
o-Phe']-octreotide was labeled with "'In as has been described elsewhere.2 Doses 
ranged from 1590 MBq to 4810 MBq lllIn, which were coupled with amounts of 
[DTPA-D-Phe'l-octreotide ranging from 10 to 120 pg. The protocol of ["IIn- DTPA- 
~-Phe']-octreotide scintigraphy has been described previ~usly.~ Radiotherapy with 
[ I 1  IIn- DTPA-~-Phel]-octreotide was applied after informed consent by the patient 
and approval by the medical ethics committee of our institution. 
CASE 
The patient is a 55-year-old female, who underwent two abdominal tumor opera- 
tions in 1988 and 1989, including partial pancreatectomy, splenectomy, and dissec- 
tion of paraaortal lymph nodes. At the second operation, liver metastases were not 
present. Histology showed a neuroendocrine tumor with positive immunohistochem- 
istry for glucagon, pancreatic polypeptide, somatostatin, calcitonin, ACTH, gastrin, 
and carcinoembryonic antigen (CEA). The patient had been referred to our hospital 
because of the demonstration of somatostatin receptors on the recurrent metastases 
according to octreotide scintigraphy. The patient never experienced signs or symp- 
toms of a hormone-producing neuroendocrine tumor. Only elevated serum levels of 
glucagon were found. Because of the excellent clinical condition of the patient at the 
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FIGURE 1. Schematic representation of gamma-ray emission (“internal conversion”) leading 
to the ejection of conversion electrons (nuclear photons transfer their energy to orbital elec- 
trons, which are then ejected from the atom, thereby leaving an electron vacancy (indicated 
with the small open circle)) and Auger electrons (the latter by X-ray photon interaction with 
a loosely bound outer electron). The maximum particle range of conversion and Auger 
electrons emitted by 111In is indicated in TABLE 1.
TABLE 1. Physical Characteristics of the Radionuclide 111In (tu = 2.83 d) 
Emission type Ea (keV) Rb ( w )  
Gamma-photons 
Conversion electrons 
Auger electrons 
17 1-245 
0.5-25 
144-245 2W550 
.02-10 
a E, energy. * R, particle range. 
TABLE 2. Energies and Yields of Conversion and Auger Electrons of 11lIn 
E (keV) Yield (percent) 
Conversion 145-170 10 
Conversion 218-245 6 
Auger 19-25 16 
Auger 2.6-3.6 102 
Auger 0.5 191 
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time of referral, it was decided not to treat her with cytostatics. Treatment with 
increasing doses of octreotide was started. Eventually therapy with interferon-a was 
started. Inasmuch as no antiproliferative effect was observed during this medical 
treatment, it was decided to investigate the effect of therapeutic doses of ["'In- 
DTPA-~-Phel]-octreotide. Neither acute nor long-term side effects, including effects 
on renal, pituitary, and bone marrow functions, were observed up to half a year after 
the last administration of a radiotherapeutic dose of ["'In- DTPA-~-Phe']-octreotide 
(data not shown). FIGURE 2 illustrates the time schedules of treatments applied to this 
patient and their effects on tumor size and both glucagon and y-glutamyl transferase 
serum levels. FIGURES 3-5 show examples of CT scans related to time and of ['llIn- 
DTPA-~-Phel]-octreotide scintigrams. It is evident that both the tumor load, and 
glucagon and y-glutamyl transferase levels react beneficially to radiotherapy. The 
decrease in glucagon levels is only transient. In accordance with the decline in 
y-glutamyl transferase levels, the CT scan of the liver shows a clear decrease in the 
size of liver metastases. 
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FIGURE 2. Results of various treatments, including radiotherapy with [ I  IIIn-DTPA-o- 
Phell-octreotide, in a patient with a metastasized inoperable glucagonoma. From 6/1990 to 
5/1992, increasing doses of (not radiolabeled) octreotide (300 to 1500 &day) were used. 
From 2/1992 to 1/1993, interferon-a (3  x 106 units three timedweek) was used. Because of 
persistent increase in size of tumor volume during this medical treatment, [IlLIn-DTF'A-D- 
Phell-octreotide was administered from 6 to 9/1992 (in 5 doses, total 15,022 MBq), and in 
2/1993 (2664 MBq) and 3/1993 (2590 MBq). The use of octreotide had been stopped before 
this radiotherapy. Tumor volume is volume of all abdominal tumors in cc, according to volume 
measurements of tumors found with whole abdominal CT scanning; glucagon and y-glutamyl 
transferase are serum levels. 
FIGURE 3. CT scanning of the here-reported case with metastasized inoperable glucago- 
noma; views are from two levels of the liver and related to time: row 1 = 23 July 1990; row 
2 = 3 June 1991; row 3 = 4 May 1992; row 4 = 17 December 1992; and row 5 = 30 August 
1993. 
FIGURE 4. Planar [111In-DTPA-~-Phe~]-octredde 
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DOSIMETRY OF ["'In- DTPA-D-P~~~I-OCTREOTIDE ACCUMULATION 
Accumulation of ["'In- DTPA-o-Phel]-octreotide in the organs with significant 
uptake, that is, liver and kidneys, and one selected abdominal tumor (mass = 300 g) 
were calculated as described b e f ~ r e . ~  Because of the high radiotherapeutic doses of 
["IIn- DTPA-o-PhelI-octreotide that were given, it was possible to scan the patient 
over a long period. An example of the course of the radioactivity is given in 
FIGURE 6. The amount of radioactivity in the liver and the tumor showed a slow 
decrease (biological half-life >700 h), whereas the radioactivity in the kidney has a 
biological half-life of about 270 hours. A total of 20 GBq (550 mCi) [II1In- DTPA- 
~-PheI]-octreotide was given intravenously in seven administrations (FIG. 2).Be- 
cause of the fact that the patient had a nephrostomy drain on the left side, only 35% 
of the produced urine entered the bladder. The urine was not collected for measure- 
ments of radioactivity. For these reasons, the dose to the urinary bladder was 
estimated using the results described previ~usly.~ The thus estimated dose to the 
urinary bladder wall was 1.3 Gy. Using the MIRDOSE2 program, the calculated 
doses on the liver and kidneys were 2.4 and 5 Gy, re~pectively.~ As the tumor had 
about the same mass as the kidneys (on the basis of the CT scans), and the radiation 
dose to the tumor was, for more than 95%, caused by the radioactivity in the tumor, 
the S-factor for the kidneys was used for the calculation of the dose on the tumor. 
The estimated apparent radiation dose to the tumor was 13 Gy. 
DISCUSSION 
Scintigraphy with [L'IIn-DTPA-~-Phel]-~ctreotide of the glucagonoma in our 
patient showed an intense accumulation of radioactivity in the tumor, indicating the 
expression of a high number of octreotide receptors. Despite the presence of octreo- 
tide receptors on the metastases, growth of the tumors continued during octreotide 
treatment, although a modest antiproliferative effect at an octreotide dose of 1500 
pg/day could not be excluded in retrospect. Also during treatment with the combina- 
tion of a high dose of octreotide and interferon-a, tumor volume continued to 
increase. Only after a cumulative dose of 20 GBq [ "lIn-DTPA-~-Phel]-octreotide, 
a decrease in total tumor volume in the abdomen of about 20% was observed. 
Furthermore, after both episodes (in 1992 and 1993) of [lllIn-DTPA-~-Phel]-octreo- 
tide radiotherapy a (transient) decline in glucagon and y-glutamyl transferase serum 
levels was observed. Possibly, these changes in serum markers can be regarded as 
signs of an antiproliferative effect of the high doses of [ '"In-DTPA-o-Phel]-octreo- 
tide. Such an effect might be comparable to the decline in thyroglobulin levels, which 
is frequently observed after successful treatment with radioactive iodine for thyroid 
cancer. It is unlikely that the peptide of ['"In-DTPA-D-Phe'l-octreotide itself in- 
FIGURE 5. Three-dimensional representation of the upper abdomen (posterior views) of the 
here-reported case with metastasized inoperable glucagonoma after injection with wmTc- 
colloid (a) and [~~~In-DTPA-~-Phe~]-octreotide (b). These scintigrams were carried out before 
the second period of radiotherapy with [ Il~ln-DTPA-~-Phel]-octreotide. Note the large "cold 
area in the upper part of the right lobe of the liver on the colloid scan and the presence of 
radioactivity in this area on the [ lllIn-DTPA-~-Phel]-octreotide scan. This difference is 
explained by the presence of somatostatin receptor expressing tumor tissue. Furthermore, the 
[I~lln-DTPA-~-Phe~]-octreotide imag shows many hot spots at various sites, representing 
metastases of the glucagonoma. 
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FIGURE 6. The percentage uptake in the kidneys, liver, and abdominal tumor area after a 
treatment dose of [111In-DTPA-o-Phel]-octreotide as function of time after injection. 
duced this effect, because of the interval of several weeks between administration of 
radioligand and the collection of the serum sample for glucagon measurement. 
Intense and homogeneous distribution of somatostatin receptors on most gluca- 
gonomas is demonstrated by [lllIn-DTPA-~-Phel]-octreotide autoradiography (not 
shown). Of course this is advantageous for PRRT with [lllIn-DTPA-~-Phe']-octreo- 
tide and might partly explain its effect in this case. The apparent radiation dose to 
the tumor (13 Gy) is calculated according to conventional dosimetry. The application 
of conventional dosimetry is validated by the fact that the range of several of the 
ionizing particles emitted is much longer than the average tumor cell diameter. 
Because of the fact that "'In is also an Auger-electron emitter (range 0.02-10 pm), 
the actual radiation dose may be much higher when the lllIn-labeled pharmaceutical 
is internalized into the cell (TABLES 1 and 2). The estimated apparent radiation dose 
to the tumor (assuming a tumor volume on the basis of the CT scan) with the 
performed radiotherapy with [lllIn-DTPA-~-Phel]-octreotide is relatively low. It is 
tempting to speculate that the observed response to this radiotherapy (because of the 
abundance of Auger electrons with a very short particle range) indicates that the 
[lllIn-DTPA-~-Phel]-octreotide is internalized into the tumor cell. In vitro tests will 
have to confirm this hypothesis. If [lllIn-DTPA-~-Phel]-octreotide is not internal- 
ized, but only binds to its receptors at the plasma membrane with the observed long 
residence time, then it may be concluded that the contribution of the conversion 
electrons (with their longer particle range than the Auger electrons) to the radio- 
therapeutic effect of [lllIn-DTPA-~-Phel]-octreotide is more important. 
However, in general, lllIn is not the most appropriate radionuclide for this 
objective, inasmuch as it lacks the preferable, higher energies of a- and p-particles. 
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It is to be expected that the radiotherapeutic use of radionuclides with those higher 
energies, coupled to small peptides, leads to higher radiation doses and more ap- 
propriate particle ranges. Also tumors with an inhomogeneous distribution of peptide 
receptors may then respond in a favorable way to this kind of treatment. lalTb is one 
of the radionuclides, which is a candidate, because it emits f3-particles and is able to 
bind to the chelator DTPA without dissociation in blood. 
Both PRS and PRRT with radiolabeled peptides(-derivatives), like hormones and 
growth factors, are at the moment in their infancy. Nevertheless, the body distribu- 
tion of small radiolabeled peptides in humans and the results of scintigraphy with 
[lllIn-DTPA-~-Phel]-octreotide are promising for PRS and PRRT. PRS might not 
only become a diagnostic localizing tool for most cancer types and their metastases, 
but it will also form the basis for PRRT with radiolabeled peptides. In general, the 
kidneys are the most critical organs for radiotherapy with radiolabeled peptides. 
Investigations are being performed to lower the renal accumulation of radioactivity 
by interrupting the tubular reabsorption of these radioligands by (1) infusion of 
amino acids (mainly lysine and arginine) and (2) transient ATP lowering in renal 
tubular  cell^.^.^ Nevertheless, the tolerable radiation dose of the kidneys seems 
already to be relatively high.'OJL Furthermore, by decreasing the renal accumulation 
of radioactivity, the cumulative dose of radiolabeled peptides for PRRT can be 
increased, thereby optimizing the ultimate radiation dose to the tumor(s). It is hoped 
that the latter can also be reached in the future by inducing an up-regulation of the 
receptor density. In conclusion, it is to be expected that the arsenal of treatment 
modalities in oncology in the near future will be extended by PRRT, using radio- 
labeled peptides(derivatives), which are more or less derived from native substances. 
This contrasts to the larger mouse monoclonal antibodies,IoJ1 of which the applica- 
tion leads to a higher background radiation and also the forming of human anti- 
mouse antibodies if administered repeatedly.'* 
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